TTI-621 clinical trial in relapsed, refractory hematological malignancies showed that systemic administration of TTI-621 could lead to CD47 blockade and dose-dependent increase in cytokines associated with phagocytosis, temporally associated with reversible thrombocytopenia, suggesting enhanced macrophage-mediated clearance of circulating platelets followed by a robust marrow regenerative response [58]. Here, CD47 is linked to hematologic disorder.